ATS: Risk of Pneumonia Up With Inhaled Corticosteroids in COPD

This article originally appeared here.
Share this content:
ATS: Risk of Pneumonia Up With Inhaled Corticosteroids in COPD
ATS: Risk of Pneumonia Up With Inhaled Corticosteroids in COPD

(HealthDay News) -- Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids (ICS) is associated with increased risk of pneumonia, but may reduce the risk of pneumonia-associated and all-cause mortality, according to research findings presented at the annual meeting of the American Thoracic Society, held from May 15 to 20 in Denver.

Ena Gupta, M.D., M.P.H., from the University of Florida College of Medicine in Jacksonville, and colleagues performed a systematic review and meta-analysis of studies involving COPD patients using ICS and a comparison arm lacking ICS. Data were included from 38 studies: 29 randomized controlled trials and nine observational trials.

The researchers found that the estimated unadjusted risk of pneumonia was increased in randomized trials and observational studies (relative risk, 1.61 [95 percent confidence interval (CI), 1.35 to 1.93] and odds ratio [OR], 1.89 [95 percent CI, 1.39 to 2.59], respectively). No difference was seen in pneumonia-associated mortality in six estimable randomized trials, while in seven estimable observational studies there was a decrease in pneumonia-associated mortality (OR, 0.72; 95 percent CI, 0.59 to 0.88). No difference was seen in the unadjusted risk of overall mortality, based on 29 randomized trials, while six observational studies showed a decrease in overall mortality in the ICS group (OR, 0.79; 95 percent CI, 0.65 to 0.97).

"This benefit may be due to the immunosuppressive and anti-inflammatory effects of ICS treatment," Gupta said in a statement.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »